Cardiogenic shock temporally associated with COVID-19 vaccination after prior COVID-19 infection: A case report

Area of Science:

• Immunology
• Cardiology
• Vaccinology

Background:

• The widespread use of COVID-19 vaccines has significantly reduced disease transmission.
• While generally safe, rare adverse events like myocarditis have been reported post-vaccination, particularly in young males.
• Multisystem Inflammatory Syndrome in Adults (MIS-A) is a rare but serious condition associated with prior SARS-CoV-2 infection.

Purpose of the Study:

• To report a unique case of MIS-A following COVID-19 vaccination.
• To highlight the clinical presentation and management of this rare post-vaccination complication.
• To inform clinicians about a potential association between COVID-19 vaccination and MIS-A.

Main Methods:

• Case report of a previously healthy 21-year-old male.
• Detailed clinical presentation including fever, leukocytosis, and severe cardiac illness.
• Diagnostic workup including COVID-19 nucleocapsid serology.
• Management of complications including cardiogenic shock and VA-ECMO support.

Main Results:

• The patient developed MIS-A after the second dose of the Pfizer-BioNTech vaccine.
• Clinical findings were consistent with MIS-A, including cardiac involvement.
• The patient required venoarterial extracorporeal membrane oxygenation (VA-ECMO) for cardiogenic shock.
• COVID-19 nucleocapsid serology was positive, suggesting a possible link to prior infection or a vaccine-induced immune response.

Conclusions:

• This case suggests a potential, albeit rare, association between Pfizer-BioNTech COVID-19 vaccination and the development of MIS-A.
• Clinicians should maintain awareness of MIS-A as a possible diagnosis in young adults presenting with severe systemic illness post-vaccination.
• The overwhelming benefits of COVID-19 vaccination in preventing severe disease and death remain paramount.